Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Spark Therap (NQ: ONCE )

N/A USD UNCHANGED
Last Price Updated: 12:31 PM EST, Dec 17, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Spark Therap

< Previous 1 2 3 4 5 6 Next >
Spark Therapeutics Reports 2015 Financial Results and Business Highlights
Spark Therapeutics (NASDAQ:ONCE) today announced financial results for the year ended December 31, 2015 and updated investors on its operational progress. The company highlighted advances made... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Acquisition of Genable Technologies
Spark Adds New Program for One of the Leading Causes of Inherited Retinal Disease, Broadening Its Pipeline of Potential Treatments for Rare Blinding Conditions 
From GlobeNewswire News Releases
Spark Therapeutics Announces Cowen Healthcare Conference Participation
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at the Cowen 36th Annual Health Care Conference on... 
From GlobeNewswire News Releases
Spark Therapeutics, Inc. to Host Conference Call on March 9th at 8:30 a.m. to Discuss 2015 Results
Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, March 9, 2016 at 8:30 a.m. Eastern to report corporate and financial results for the year ended... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Launch of aSharedVision, a New Online Resource to Unite and Inform Those Affected by Inherited Retinal Diseases
Spark Therapeutics (NASDAQ:ONCE) today announced the launch of aSharedVision (www.aSharedVision.com), a new online resource designed to help patients, caregivers and health care professionals better... 
From GlobeNewswire News Releases
Emerald Investment Conference Shadows Groundhog Day – Investment Professionals Gathering in Philadelphia on February 3rd
Investment professionals to meet on Feb. 3rd for the Emerald Asset Management Groundhog Day Investment Forum as analysts & portfolio managers discuss strategic investment themes and trends for 2016. 
From Business Wire News Releases
WHAT’S AHEAD FOR 2016: Investment Trends and Themes to be Highlighted at the Emerald Groundhog Day Investment Forum
Emerald Asset Management presents the Groundhog Day Investment Forum on February 3rd in Philadelphia as Emerald’s analysts and portfolio managers present key investment themes and trends for 2016 
From Business Wire News Releases
Spark Unveils Vision of Having 10 Clinical-Stage Gene Therapy Programs by 2018, Including One Commercial and Two in Pivotal Trials
Spark Therapeutics Inc. (NASDAQ:ONCE) today outlined a comprehensive three-year vision for expanding the company’s portfolio through 2018 and launching its first commercial product in 2017, during a... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Addition of Lota Zoth to Its Board of Directors
Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today that Lota Zoth, CPA, a long-time financial executive at multiple publicly listed companies, has been named to the company’s Board of Directors. 
From GlobeNewswire News Releases
Spark Therapeutics Announces J.P. Morgan Healthcare Conference Participation
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at the J.P. Morgan 34th Annual Healthcare Conference on... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Pricing of Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $47.00 per share,... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Launch of Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. The offering consists of 2,000,000 shares... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Addition to NASDAQ Biotechnology Index
Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today that it has been selected by NASDAQ for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI). The annual re-ranking of the NASDAQ... 
From GlobeNewswire News Releases
Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer for Progress in Hemophilia B Gene Therapy Program
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has earned a $15 million milestone payment from Pfizer Inc. (“Pfizer”) (NYSE:PFE) under the companies’ global collaboration for... 
From GlobeNewswire News Releases
Spark Therapeutics Announces December Conference Participation
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that members of its management team will participate in three upcoming conferences throughout December: 
From GlobeNewswire News Releases
Spark Therapeutics Announces Filing of Registration Statement for Proposed Public Offering
The Children’s Hospital of Philadelphia Foundation to be a Selling Stockholder 
From GlobeNewswire News Releases
Spark Therapeutics Announces Presentation of Additional Phase 3 Data on SPK-RPE65 at The American Academy of Ophthalmology 2015 Annual Meeting
Presentation Highlights Positive Trend in Visual Acuity, Together With Highly Statistically Significant Positive Results in Primary and First Two Secondary Efficacy Endpoints 
From GlobeNewswire News Releases
Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease
Preclinical Data Published in Science Translational Medicine Demonstrate Delay in Onset and Progression of a Form of Batten Disease 
From GlobeNewswire News Releases
Spark Therapeutics Reports Third Quarter 2015 Financial Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE) today announced financial results for the quarter ended September 30, 2015 and updated investors on its operational progress. 
From GlobeNewswire News Releases
Spark Therapeutics, Inc. to Host Conference Call on November 4th at 8:30a.m. to Discuss Third Quarter 2015 Results
Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, November 4, 2015 at 8:30 a.m. Eastern to report corporate and financial results for the three and nine... 
From GlobeNewswire News Releases
Spark Therapeutics to Participate in Four Conferences in October and November
Spark Therapeutics (NASDAQ:ONCE) announced today that members of its management team will participate in four upcoming conferences throughout October and November: 
From GlobeNewswire News Releases
Spark Therapeutics Announces Presentation of Additional Phase 3 and Durability Data on SPK-RPE65 at The Retina Society 48th Annual Scientific Meeting
Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today the presentation of additional data from the Phase 3 pivotal trial as well as continued durability data from an earlier Phase 1 study of... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial of SPK-RPE65 for Genetic Blinding Conditions
Spark Therapeutics (NASDAQ:ONCE) today announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated... 
From GlobeNewswire News Releases
Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration
Clearside Biomedical, which develops first-in-class drug therapies to treat diseases of the eye, announces enrollment of 50th patient using suprachoroidal (SCS™) drug administration. 
From Business Wire News Releases
Spark Therapeutics Announces Database Lock for SPK-RPE65 Phase 3 Clinical Trial and Expected Release of Top-Line Data in October
From GlobeNewswire News Releases
Poseida Therapeutics, Inc., Expands Board of Directors
From GlobeNewswire News Releases
Spark Therapeutics Reports Second Quarter 2015 Results
Confirming Guidance for Phase 3 Data Readout for SPK-RPE65 in 2015; Pipeline Advancing and Expanding 
From GlobeNewswire News Releases
Spark Therapeutics, Inc. to Host Conference Call on August 5th at 8:30a.m. to Discuss Second Quarter 2015 Results
From GlobeNewswire News Releases
Spark Therapeutics to Present With Pfizer Inc. Preclinical Data on Their Lead SPK-FIX Product Candidate for Hemophilia B at the 2015 International Society of Thrombosis and Haemostasis Congress in Jun
From GlobeNewswire News Releases
Spark Therapeutics to Participate in Two International Conferences in London in June
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.